Biotricity has received FDA 510 (k) approval for heart control devices –

0
62


What you should know:

Biotricity, Inc. (NASDAQ: BTCY), a medical diagnostics and consumer healthcare technology company, announced today that it has received 510 (k) approval from the U.S. Food and Drug Administration (FDA) for its heart monitoring device. Biotres, a three-lead device for ECG and arrhythmia monitoring for lower-risk patients.

– Most remote heart rate monitors are passive (do not record ECG and other cardiac data in real time) and do not have cross-compatibility with other platforms / devices. In contrast, Biotricity’s expanding set of cardiac monitoring technologies is a turnkey solution that offers the advanced and continuous type of monitoring that allows cardiologists to see warning signs before and act proactively and integrates seamlessly. to existing systems. Biotres is not only expanding our product portfolio, but also opening a new market and increasing the total addressable Biotricity market from $ 1 billion to $ 5.7 billion and will be widely available for sale from on April 1, 2022.

– The Biotres not only expands our product portfolio, but also opens a new market and increases Biotricity’s total addressable market from $ 1 billion to $5.7 billion and will be widely available for sale from April 1, 2022.



Source link